Maecke HR - Search Results

1

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Forrer F, et al. Among authors: maecke hr. J Nucl Med. 2005 Aug;46(8):1310-6. J Nucl Med. 2005. PMID: 16085587 Free article. Clinical Trial.

2

Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.

Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke HR, Mueller-Brand J, Lohri A. Forrer F, et al. Among authors: maecke hr. J Nucl Med. 2013 Jul;54(7):1045-52. doi: 10.2967/jnumed.112.115170. Epub 2013 Apr 9. J Nucl Med. 2013. PMID: 23572496 Free article. Clinical Trial.

3

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Waldherr C, et al. Among authors: maecke hr. J Nucl Med. 2002 May;43(5):610-6. J Nucl Med. 2002. PMID: 11994522 Free article.

4

Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.

Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Forrer F, et al. Among authors: maecke hr. Anticancer Res. 2006 Jan-Feb;26(1B):703-7. Anticancer Res. 2006. PMID: 16739341 Free article. Clinical Trial.

5

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. Waldherr C, et al. Among authors: maecke hr. Ann Oncol. 2001 Jul;12(7):941-5. doi: 10.1023/a:1011160913619. Ann Oncol. 2001. PMID: 11521799 Free article. Clinical Trial.

6

A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.

Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR. Forrer F, et al. Among authors: maecke hr. Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1257-62. doi: 10.1007/s00259-004-1553-6. Epub 2004 Jun 10. Eur J Nucl Med Mol Imaging. 2004. PMID: 15197500 Clinical Trial.

7

Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.

Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Forrer F, et al. Among authors: maecke hr. Q J Nucl Med Mol Imaging. 2008 Dec;52(4):334-40. Epub 2008 May 16. Q J Nucl Med Mol Imaging. 2008. PMID: 18480742 Clinical Trial.

8

90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.

Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. Gerster-Gilliéron K, et al. J Nucl Med. 2015 Nov;56(11):1748-51. doi: 10.2967/jnumed.115.155853. Epub 2015 Aug 20. J Nucl Med. 2015. PMID: 26294303 Free article. Clinical Trial.

9

Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.

Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR. Abiraj K, et al. Among authors: maecke hr. J Nucl Med. 2011 Dec;52(12):1970-8. doi: 10.2967/jnumed.111.094375. Epub 2011 Nov 11. J Nucl Med. 2011. PMID: 22080443 Free article.

10

Radiopeptide imaging and therapy in Europe.

Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Ambrosini V, et al. Among authors: maecke hr. J Nucl Med. 2011 Dec;52 Suppl 2:42S-55S. doi: 10.2967/jnumed.110.085753. J Nucl Med. 2011. PMID: 22144555 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters